Avacta signs technology agreement
Diagnostics specialist Avacta has entered into a commercial partnership to develop and commercialise its synthetic Affimers, a high-tech alternative to antibodies, for the most widely used multi-test platform worth some £177m a year.
Wetherby-based Avacta has formed a partnership with ProtATonce to provide a range of Affimers to be used in kits that will enable large numbers of tests to be conducted on a single sample at the same time. The kits could be capable of carrying out up to 500 tests in one experiment which is impossible using antibodies.
Analysts at Panmure Gordon said: “The Luminex xMAP platform is market leading and multiple organisations compete to provide new assays which, if successful, would be integrated into the Luminex platform and rolled out into commercial use with greater ease.”